INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE
Abstract
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>INTRODUCTION</jats:title>
<jats:p>The use of telemedicine increased during the COVID-19 pandemic. However, the
impact on patient satisfaction in the Neuro-oncology population is unknown. This quality
improvement project compares outpatient satisfaction before and during the COVID-19
pandemic as well as in-person versus telemedicine platforms during the pandemic.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>METHODS</jats:title>
<jats:p>We performed an IRB-exempt retrospective analysis of aggregate de-identified
outpatient satisfaction scores among Neuro-oncology patients seen at The Preston Robert
Tisch Brain Tumor Center (PRTBTC) at Duke University. The Clinician & Group Consumer
Assessment of Healthcare Providers and Systems (CG-CAHPS) is a survey developed and
distributed by Press Ganey Associates, and is the most widely used outpatient satisfaction
survey in the United States. We compared pre-COVID-19 CG-CAHPS scores from patients
who received in-person care at the PRBTC between April 2019 and March 2020 to COVID-19
pandemic CG-CAHPS scores (i.e. those who received either telemedicine or in-person
care at the PRTBTC) from April 2020 to March 2021.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>RESULTS</jats:title>
<jats:p>Approximately 1448 surveys were completed for both in-person and telemedicine
visits. During the pandemic, 48.6% of surveys represented telemedicine, with monthly
variations from 84.6% (April 2020) to 21.4% (March 2021). Patient satisfaction scores
pre-COVID-19 were similar to those during the pandemic: overall provider rating from
0-10 (9.28 v 9.36), knowledge of medical history (96.9% v 95.4%), listens carefully
(96.6% v 96.9%), shows respect (97.2% v 98.1%), and time spent (93.2% v 95.5%). During
the COVID-19 pandemic, in-person and telemedicine demonstrate similar levels of satisfaction:
overall provider rating from 0-10 (9.29 v 9.48), knowledge of medical history (94.9%
v 96.1%), listens carefully (95.4% v 99.0%), shows respect (97.5% v 99.0%), and time
spent (94.7% v 96.7%).</jats:p>
</jats:sec>
<jats:sec>
<jats:title>CONCLUSION</jats:title>
<jats:p>Outpatient satisfaction prior to and during the COVID-19 pandemic was similar.
Patients reported similar satisfaction between in-person and telemedicine platforms.
We support the ongoing use of telemedicine for outpatient Neuro-oncology.</jats:p>
</jats:sec>
Type
Journal articlePermalink
https://hdl.handle.net/10161/24052Published Version (Please cite this version)
10.1093/neuonc/noab196.442Publication Info
Petitt, Zoey; Herndon, James; Gottfried, Oren; Cone, Christina; Landi, Daniel; Khasraw,
Mustafa; ... Johnson, Margaret (2021). INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19
TELEMEDICINE. Neuro-Oncology, 23(Supplement_6). pp. vi112-vi112. 10.1093/neuonc/noab196.442. Retrieved from https://hdl.handle.net/10161/24052.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
David Michael Ashley
Rory David Deutsch Distinguished Professor of Neuro-Oncology
Dr. Ashley's primary research focus is laboratory based, investigating the role of
immunotherapy as a novel approach to the treatment of tumors of the central nervous
system (CNS). Since beginning his appointment at the faculty level at Duke in August
of 1995 his activities have centered on two main areas of investigation. The first
involves both in vivo and in vitro studies of the use of molecular therapeutics to
target a CNS tumor associated antigen. The second area of interest comprises a det
Margaret Johnson
Assistant Professor of Neurosurgery
I am a neuro-oncologist, neurologist, and palliative care physician at the Preston
Robert Tisch Brain Tumor Center. I also provide neuro-oncology expertise for the National
Tele-Oncology Program and National Precision Oncology Program at the Veteran's Health
Administration. My clinical and research interests encompass supportive care and palliative
care with a special interest in older adults with brain tumors. The incidence of malignant
brain tumors like glioblastoma and non-malignant tumors li
Mustafa Khasraw
Professor of Neurosurgery
I am a physician-scientist, a medical oncologist, a neuro-oncologist, a tenured professor
of medicine and neurooncology, and Deputy Director of the Center for Cancer Immunotherapy,
Duke Cancer Institute, where we are tasked to speed up clinical research and translation
for scientists across all departments and all tumor types at Duke, who have made discoveries
that show promise for developing new immune and T cell-based therapies.
I lead a Tumor Immunobiology (TIL) Lab aiming to
Daniel Bryce Landi
Assistant Professor of Pediatrics
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info